Yerace Daniel Alexander 4

What Happened Daniel Alexander Yerace, Vice President of Operations and a company director at Coeptis Therapeutics (COEP), acquired shares in two related transactions on February 11, 2026. He exercised 10,000 stock options at a weighted-average exercise price of $10.41 per share (total cash paid: $104,100) and was granted 20,000 restricted shares at no cash cost as part of an option-exchange program.

Key Details

• Transaction date: 2026-02-11 (reported on Form 4 filed 2026-02-13; filing appears timely).
• Option exercise: 10,000 shares acquired at $10.41 each (total $104,100). (Code M)
• Restricted stock grant: 20,000 shares issued at $0.00 (no cash paid). (Code A)
• Footnote F1: the $10.41 reflects the weighted-average exercise price of the options exercised.
• Footnote F2: the restricted stock was issued in connection with an option-exchange program in which the reporting person surrendered underwater options in exchange for restricted stock.
• Shares owned after the transactions: not specified in the provided excerpt of the filing.
• No sale of shares was reported as part of these transactions; no indication of a cashless sale or immediate disposition in the provided data.

Context

• Exercising options is an acquisition (the insider paid the exercise price to convert options into common shares); this differs from an open-market purchase because it uses previously granted option rights rather than buying stock on the market.
• The restricted stock grant resulted from an option-exchange program (per F2), a corporate action that replaces underwater options with restricted shares—this is not a market purchase or a gift.
• These transactions are factual disclosures of insider activity and do not, by themselves, indicate the insider’s view of the company’s prospects.